ISRG Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 21.47%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Johnson & Johnson's return on equity of 33.27%.

Intuitive Surgical, Inc. has a consensus price target of $592.96, signalling upside risk potential of 4.08%. On the other hand Johnson & Johnson has an analysts' consensus of $202.54 which suggests that it could fall by -1.36%. Given that Intuitive Surgical, Inc. has higher upside potential than Johnson & Johnson, analysts believe Intuitive Surgical, Inc. is more attractive than Johnson & Johnson.

Intuitive Surgical, Inc. has a beta of 1.682, which suggesting that the stock is 68.249% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.296%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.5% to investors and pays a quarterly dividend of $1.30 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are smaller than Johnson & Johnson quarterly revenues of $24B. Intuitive Surgical, Inc.'s net income of $709.2M is lower than Johnson & Johnson's net income of $5.2B. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 75.41x while Johnson & Johnson's PE ratio is 19.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 21.55x versus 5.40x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Stryker Corp. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 14.18%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Stryker Corp.'s return on equity of 14.06%.

Intuitive Surgical, Inc. has a consensus price target of $592.96, signalling upside risk potential of 4.08%. On the other hand Stryker Corp. has an analysts' consensus of $428.96 which suggests that it could grow by 17.22%. Given that Stryker Corp. has higher upside potential than Intuitive Surgical, Inc., analysts believe Stryker Corp. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.682, which suggesting that the stock is 68.249% more volatile than S&P 500. In comparison Stryker Corp. has a beta of 0.890, suggesting its less volatile than the S&P 500 by 11.047%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker Corp. offers a yield of 0.92% to investors and pays a quarterly dividend of $0.84 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Stryker Corp. pays out 41.74% of its earnings as a dividend. Stryker Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are smaller than Stryker Corp. quarterly revenues of $6.1B. Intuitive Surgical, Inc.'s net income of $709.2M is lower than Stryker Corp.'s net income of $859M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 75.41x while Stryker Corp.'s PE ratio is 48.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 21.55x versus 5.80x for Stryker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 14.58%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat Thermo Fisher Scientific, Inc.'s return on equity of 13.15%.

Intuitive Surgical, Inc. has a consensus price target of $592.96, signalling upside risk potential of 4.08%. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $619.96 which suggests that it could grow by 6.81%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.682, which suggesting that the stock is 68.249% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.899, suggesting its less volatile than the S&P 500 by 10.144%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.29% to investors and pays a quarterly dividend of $0.43 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.43% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $11.1B. Intuitive Surgical, Inc.'s net income of $709.2M is lower than Thermo Fisher Scientific, Inc.'s net income of $1.6B. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 75.41x while Thermo Fisher Scientific, Inc.'s PE ratio is 33.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 21.55x versus 5.04x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of 28.31% compared to Intuitive Surgical, Inc.'s net margin of 17.41%. Intuitive Surgical, Inc.'s return on equity of 16.38% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Intuitive Surgical, Inc. has a consensus price target of $592.96, signalling upside risk potential of 4.08%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $346.07 which suggests that it could grow by 21.72%. Given that West Pharmaceutical Services, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe West Pharmaceutical Services, Inc. is more attractive than Intuitive Surgical, Inc..

Intuitive Surgical, Inc. has a beta of 1.682, which suggesting that the stock is 68.249% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.166, suggesting its more volatile than the S&P 500 by 16.617%.

Intuitive Surgical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.3% to investors and pays a quarterly dividend of $0.22 per share. Intuitive Surgical, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intuitive Surgical, Inc. quarterly revenues are $2.5B, which are larger than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Intuitive Surgical, Inc.'s net income of $709.2M is higher than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Intuitive Surgical, Inc.'s price-to-earnings ratio is 75.41x while West Pharmaceutical Services, Inc.'s PE ratio is 42.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intuitive Surgical, Inc. is 21.55x versus 6.86x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.